Add like
Add dislike
Add to saved papers

Multifunctional Yolk-Shell Mesoporous Silica Obtained via Selectively Etching the Shell: A Therapeutic Nanoplatform for Cancer Therapy.

Herein, we fabricated a new yolk-shell-structured mesoporous silica nanoparticle (YMSN) with multifunctionalities of fluorescence imaging, photothermal therapy (PTT), and drug delivery by using a fluorescein isothiocyanate-doped silica nanoparticle partially covered by patchy gold as the core. Different from the conventional selective etching procedure, the multifunctional silica core is left intact, and the alkali etching mainly occurs in a hexadecyl trimethyl ammonium bromide/silica hybrid layer, which leads to the formation of the void space in YMSNs. In addition, the utilization of patchy gold as the PTT agent can avoid the shield against the outer irradiation on the core. Results show that the as-prepared YMSNs have a good biocompatibility in the concentration of 0-1000 μg·mL-1 and a high doxorubicin-loading capability (8.04 wt %). In vitro and in vivo antitumor experiments reveal that the resulting YMSNs can be utilized for chemo- and photothermic combination therapy as well as optical imaging.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app